News
GlyTherix Ltd is presenting at AusBiotech Asian Investment Series
GlyTherix Ltd is one of 25 Australian life science companies presenting new business opportunities to international investors during the Asian investment series, hosted by AusBiotech. The events are on 26 March in Hong Kong and 28-29 March in Shanghai and will attract...
read more
Minomic announces completion of demerger of GlyTherix Ltd
Demerger clears the path for therapeutic company capital raising Sydney, Australia, 25 September 2018: Minomic International Ltd is pleased to announce it received strong shareholder approval to approve the demerger of its therapeutic subsidiary, GlyTherix Ltd,...
read more
Minomic announces completion of accrual for clinical study of Miltuximab® in prostate, bladder and pancreatic cancers
No drug-related adverse effects found in patients Sydney, Australia, 24th July 2018: Minomic International Ltd (Minomic) is an immuno-oncology company specializing in therapeutics and diagnostics for solid tumors, including prostate, bladder and pancreas. The Company...
read more
ASCO meeting abstract: Glypican-1 as a novel immunotherapeutic target in prostate cancer
A poster on Glypican-1 as a novel immunotherapeutic target in genitourinary cancers was presented by Dr Douglas Campbell, Minomic's head of R&D at the 2018 ASCO Genitourinary Cancers Symposium in San Francisco. Preliminary in vitro ADCC assay results revealed the...
read more
Minomic clinical study progresses for Miltuximab® in prostate, bladder, and pancreatic cancer
June 27, 2017: [Sydney] Australian immuno-oncology company Minomic International Ltd is proceeding to the second stage of its pioneering MILGa clinical trial of Miltuximab®, a chimeric version of Minomic’s MIL-38 anti-Glypican-1 antibody conjugated to the radioactive...
read more
Minomic Announces Clinical Study Update for MILGa in Prostate, Bladder and Pancreatic Cancers
No Adverse Effects Found in Patients Dosed To-Date Sydney, Australia, 5 January 2017: Minomic International Ltd (Minomic) is an immuno-oncology company specializing in therapeutics and diagnostics for solid tumors, including prostate, bladder, and pancreas. The...
read more
Minomic launches first-in-human clinical trial of radioactive anti-cancer antibody
Media Release Immunotherapy targets prostate, bladder, pancreatic cancer First of 12 patients enrolled in clinical trial Treatment scheduled to begin within days Sydney, Australia, 22 August 2016: Immuno-oncology company, Minomic International, has enrolled the first...
read more